Erlotinib, a target inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, is currently recommended as a combination treatment for patients with skin rash, and is beneficial to the overall survival of patients with pancreatic cancer [4, 15]; but, immunotherapy has no efficacy in patients with pancreatic cancer due to the immunosuppressive tumor microenvironment [13]. The gene discussed is EGFR; the disease is neoplasm.